University of Minnesota. Driven to Discover.
Data on 60 million people indicate the vaccine has slashed infections and pre-cancer lesions.
Both AAP and the CDC, though, support using FluMist with the goal of optimizing vaccine coverage.
ACIP suggests vaccination by the end of October—but the start date is less clear.
A survey of primary care docs reveals significant gaps in their knowledge of serogroup B meningococcal vaccines.
The results confirm, however, that the vaccine is most effective when given at younger ages.
After careful deliberation, experts approved the nasal-spray vaccine 12-2.
Panel gives a preference to Shingrix and recommends MMR for mumps outbreaks.
Overall flu vaccine effectiveness was 48%, but a change in the 2009 H1N1 vaccine strain didn't fix the problem with the inhaled vaccine's effectiveness in children.
The vaccine offers strong protection to infants, especially during the first 2 months of life.
Healthcare providers need to offer vaccines and address vaccine hesitancy whenever possible, the AAP's Committee on Infectious Diseases says.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.